• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Pfizer Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Pfizer Reports First-Quarter 2024 Results
May 01, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
April 29, 2024
From Pfizer Inc.
Via Business Wire
Tickers GMAB PFE
News headline image
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
April 29, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
April 26, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Declares Second-Quarter 2024 Dividend
April 24, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
April 22, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
April 11, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
April 09, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
March 20, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
March 13, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
March 12, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
March 05, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth
February 29, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults
February 29, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 26, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
February 19, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day
February 15, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities
February 05, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
January 30, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
January 26, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
January 10, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
January 09, 2024
From Pfizer Inc.
Via Business Wire
Tickers GMAB PFE
News headline image
European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer
January 08, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 02, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
December 19, 2023
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
December 15, 2023
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Declares First-Quarter 2024 Dividend
December 14, 2023
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Completes Acquisition of Seagen
December 14, 2023
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Provides Full-Year 2024 Guidance
December 13, 2023
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
December 12, 2023
From Pfizer Inc.
Via Business Wire
Tickers PFE
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap